Besponsa becomes first of its kind indicated for rare type of acute lymphoblastic leukaemia.
Mylotarg backed by advisers after withdrawal in 2010.
Pfizer locks horns with NICE following EU approval.
RA drug backed after manufacturer offered discount.
Cancer drugs from Novartis and Pfizer also backed
Concerns that NICE will reject Kisqali like it did Ibrance.
Companies hope tanezumab offers alternative to opioids